price may usd
buy rate reflect view compani growth trajectori
durabl multipl defens result compani miss
organ sale growth forecast detract thesi
thing like
 pocket out-performance pharma system bioscienc
although miss organ sale growth enterpris level
pocket out-performance worth call view
march quarter pharmaceut system growth surpass
forecast grew light advers impact time order
pull sale previou quarter addit bioscienc growth
handili beat forecast bioscienc front seem
keep pace healthi growth report tool peer
thing cautiou
sale growth came forecast consensu
miss versu dbe driven lower growth bd medic
segment manag attribut lower sale growth primarili two
factor includ impact distributor inventori adjust
 medic deliveri solut md busi headwind
md busi outlook dcb busi growth hing
upcom fda panel june
lower adj ep guid rang fx dcb-relat issu
lower adj ep guid rang declin
 reflect headwind fx recent regulatori
market pressur relat drug coat balloon dcb
margin flow much sever expect increment
top-lin headwind fx dcb-relat issu seemingli much
higher drop bottom line anticip stem
greater drop relat non-europ currenc
account increment headwind owe broad-bas
strengthen dollar strong margin dcb busi
exacerb inabl find cost offset continu
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
manufactur product lower volum advanc june fda
panel manag also note expect increment dcb headwind
includ relat anticip launch lutonix below-the-
lower growth expect intervent segment
expect constant currenc compar sale growth
bd intervent segment basi point bp lower
previou guidanc rang downward revis primarili
stem regulatori market issu drug coat balloon dcb
pt
lower price target reflect lower ebitda
forecast lower ev/ebitda multipl partial off-set roll forward
valuat framework price target reflect enterpris valu use project
level debt cash adjust ebitda forecast trail
twelv month end lower appli ev/ebitda multipl
previou reflect lower sale ep growth forecast multipl
in-lin core peer median discount core tool peer
period end expens stock incom ep share share sale ex acquir intang cash flowoper cash cash neutral sale growth dilut
period end asset cash receiv expens defer tax current plant intang asset liabil current portion short term expens current debt net incom tax long-term liabil stockhold may
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
